DAX ®12.543,54-1,81%TecDAX ®2.989,48-1,77%S&P FUTURE3.093,60-0,53%Nasdaq 100 Future8.936,75+0,93%
finanztreff.de

DGAP-Adhoc: Xlife Sciences AG: Capital Increase 'Private Placement'

| Quelle: Dow Jones Newsw... | Lesedauer etwa 2 min. | Text vorlesen Stop Pause Fortsetzen


DGAP-Ad-hoc: Xlife Sciences AG / Key word(s): Capital Increase
Xlife Sciences AG: Capital Increase 'Private Placement'

14-Feb-2020 / 14:14 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

*Xlife Sciences AG: Capital Increase 'Private Placement'*

Based on the resolution of the Board of Directors on 14th of February 2020
(resolution of the general assembly on 25th of October 2018), Xlife Sciences
AG has decided to execute a "private placement" from authorized capital,
260'000 shares at a share price of CHF 33.50.- (EUR 30.70.-, average share
price over the 30 last trading days, EUR/CHF average rate ESTV 1.0912).
Xlife Sciences AG will direct more investments towards employees in research
and development. In addition, the project portfolio will be further
diversified.

*Xlife Sciences AG*

Xlife Sciences AG is a Swiss company with focus on investing in promising
technologies in the life science industry. Xlife Sciences AG is buildingthe
bridge from research and development to healthcare markets by supporting
researchers and entrepreneurs in positioning, structuring, developing and
implementing their concepts. Together with industrial partners or
universities, Xlife Sciences AG leads projects through the proof-of-concept
phase after an invention disclosure or start-up. Subsequently, the firm
focuses on out-licensing or selling the company, often with a combination of
a strategic partnership. Xlife Sciences AG offers its investors direct
access to the further development of innovative and future-oriented
technologies at a very early stage.
For more information, please visit: www.xlifesciences.ch [1]

14-Feb-2020 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Xlife Sciences AG
Klausstrasse 19
8008 Zürich
Switzerland
Phone: 0041 44 385 84 60
E-mail: info@xlifesciences.ch
Internet: www.xlifesciences.ch
ISIN: CH0461929603
WKN: A2PK6Z
Listed: Regulated Unofficial Market in Munich
EQS News ID: 975861

End of Announcement DGAP News Service

975861 14-Feb-2020 CET/CEST


1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=90cbe54b2705cc78ac2cc5fee6b5091f&application_id=975861&site_id=vwd&application_name=news


(END) Dow Jones Newswires

February 14, 2020 08:14 ET ( 13:14 GMT)
Werbung

Das könnte Sie auch interessieren

News-Suche

Suchbegriff:

Aktuelle Videos

HSBC Trading TV

Werbung

Trading-Tipp

Börsen & Märkte

US-Marktüberblick

zur Mediathek
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Die Lufthansa und ihre Partnerin United Airlines erwägen eine Übernahme der Fluggesellschaft TAP Portugal. Glauben Sie, dass es dazu kommen wird?
Jetzt abstimmen!
Alle Umfragen ansehen